Healthcare antitrust, settlements, and the Federal Trade Commission /:
This volume of Research in Law and Economics contains articles that address important legal and economic developments in the areas of healthcare, intellectual property and labor settlements, competitive effects, cartel overcharges, and the U.S. Federal Trade Commission (""FTC"").
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Bingley, UK :
Emerald Publishing,
2018.
|
| Ausgabe: | First edition. |
| Schriftenreihe: | Research in law and economics (Emerald Publishing (Firm)) ;
v. 28. |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | This volume of Research in Law and Economics contains articles that address important legal and economic developments in the areas of healthcare, intellectual property and labor settlements, competitive effects, cartel overcharges, and the U.S. Federal Trade Commission (""FTC""). |
| Beschreibung: | 1 online resource |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9781787565999 1787565998 9781787566019 1787566013 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBU-on1049149977 | ||
| 003 | OCoLC | ||
| 005 | 20240405112445.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 180821s2018 enk ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d N$T |d EBLCP |d YDX |d OCLCF |d NLE |d MERUC |d COO |d UKMGB |d OCLCQ |d OTZ |d CAUOI |d UKAHL |d OCLCQ |d VT2 |d K6U |d OCLCO |d OCLCQ |d OCLCO |d OCLCL | ||
| 016 | 7 | |a 018893821 |2 Uk | |
| 019 | |a 1049603806 |a 1049935205 |a 1170519398 |a 1171039283 |a 1262687076 | ||
| 020 | |a 9781787565999 |q (electronic bk.) | ||
| 020 | |a 1787565998 |q (electronic bk.) | ||
| 020 | |a 9781787566019 | ||
| 020 | |a 1787566013 | ||
| 020 | |z 9781787566002 | ||
| 020 | |z 1787566005 | ||
| 035 | |a (OCoLC)1049149977 |z (OCoLC)1049603806 |z (OCoLC)1049935205 |z (OCoLC)1170519398 |z (OCoLC)1171039283 |z (OCoLC)1262687076 | ||
| 037 | |a 9781787566019 |b Emerald Publishing | ||
| 043 | |a n-us--- | ||
| 050 | 4 | |a KF3827.A58 | |
| 072 | 7 | |a LAW |x 001000 |2 bisacsh | |
| 072 | 7 | |a KC |2 bicssc | |
| 080 | |a 343 | ||
| 082 | 7 | |a 344.730321 |2 23 | |
| 049 | |a MAIN | ||
| 245 | 0 | 0 | |a Healthcare antitrust, settlements, and the Federal Trade Commission / |c edited by James Langenfeld, Edwin Galeano. |
| 250 | |a First edition. | ||
| 264 | 1 | |a Bingley, UK : |b Emerald Publishing, |c 2018. | |
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Research in law and economics ; |v volume 28 | |
| 504 | |a Includes bibliographical references and index. | ||
| 588 | |a Online resource; title from PDF title page (EBSCO, viewed August 23, 2018). | ||
| 505 | 0 | |a Front Cover; Healthcare Antitrust, Settlements, and the Federal Trade Commission; Copyright Page; Contents; About the Editors; List of Contributors; Acknowledgments; Introduction; "To Know Where You're Going, Look at Where You've Been"; Introduction; Pharmaceuticals: A Case of FTC Investment and Consumption; Provider Mergers: Clear Guidance from Litigated Cases; No Need for Special Rules for Healthcare Markets; ACKNOWLEDGMENT; Notes; References; Actavis, Authorized Generics, and the Future of Antitrust Law; Introduction; Background; Merits Analysis; Hatch-Waxman Background. | |
| 505 | 8 | |a Applying Merits Analysis to Hatch-WaxmanPre-Actavis Analysis of Hatch-Waxman Settlements; Federal Trade Commission v. Actavis; Understanding Actavis; Bribing Generics to Stay Out of the Market; Hypotheticals; H1. The Litigants' Expectations about Litigation are Correct; H2. The Parties Both Believe that the Brand Holds a "Strong" Patent; H3. No Alignment in Expectations; H4. Pessimistic Litigants Split the Patent Life with No Net Reverse Payment; H5a. The Brand Prevailed in a Litigation Challenging Patent Validity but Settles a Second Challenge. | |
| 505 | 8 | |a H5b. The Settlement Fails and the Parties Continue to LitigateH6. No Alignment in Expectations but Risk Aversion Leads to Settlements; H7a. Efficiencies; H7b. Efficiencies; Some Conclusions Derived from the Hypotheticals; Without Legal Limitations, There Will Be Anticompetitive Hatch-Waxman Settlements; Actavis Abandons the Preponderance-of-the-Evidence Standard for Determining Anticompetitive Effects; If the Parties' Expectations Are Correct, Absent Risk Aversion, on Average, Consumers Are Often No Better Off with the Acta ... ; Not Accounting for Risk Profiles May Harm Consumers. | |
| 505 | 8 | |a Actavis Relies on Intent EvidenceActavis Relies on the Intent of the Brand, Not Necessarily the Generic; If the Parties' Expectations Are Not Correct, the Actavis Solution May Make Consumers Worse Off than Merits Analysis; Even in a Settlement without a Net Reverse Payment, One of the Parties May Intend to Achieve an Anticompetitive Effect; Actavis Circumvents Other Elements of Conventional Antitrust Analysis; A Red Flag Is Central to the Actavis Methodology; There Is No Easy Means of Balancing Efficiencies against Anticompetitive Effects Using the Actavis Methodology. | |
| 505 | 8 | |a Additional Unresolved Actavis IssuesAntitrust Injury; Damages; The Slippery Slope of Mt. Actavis; The No-AG Agreement; Applying Actavis to Difficult IP/Antitrust Cases; Antitrust Guidelines for the Licensing of Intellectual Property; Actavis beyond the IP/Antitrust Interface; Where Are We Going?; Notes; Acknowledgment; References; Solving the Product-Hopping Conundrum through Safe Harbors and a No-Economic-Sense Test; Introduction; Product Hopping; Forms of Product Hopping; Hatch-Waxman Act; State Drug Product Selection Laws; Timing of Generic Entry; A New Product-Hopping Framework. | |
| 520 | |a This volume of Research in Law and Economics contains articles that address important legal and economic developments in the areas of healthcare, intellectual property and labor settlements, competitive effects, cartel overcharges, and the U.S. Federal Trade Commission (""FTC""). | ||
| 650 | 0 | |a Antitrust law |z United States. | |
| 650 | 0 | |a Medical care |x Law and legislation |z United States. | |
| 650 | 7 | |a Economics. |2 bicssc | |
| 650 | 7 | |a LAW |x Administrative Law & Regulatory Practice. |2 bisacsh | |
| 650 | 7 | |a Antitrust law |2 fast | |
| 650 | 7 | |a Medical care |x Law and legislation |2 fast | |
| 651 | 7 | |a United States |2 fast |1 https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq | |
| 700 | 1 | |a Langenfeld, James, |e editor. | |
| 700 | 1 | |a Galeano, Edwin, |e editor. | |
| 758 | |i has work: |a Healthcare antitrust, settlements, and the Federal Trade Commission (Text) |1 https://id.oclc.org/worldcat/entity/E39PCGGjbHQqHHDhBTwQ684MKd |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |t Healthcare antitrust, settlements, and the Federal Trade Commission. |b First edition. |d Bingley, UK : Emerald Publishing, 2018 |z 1787566005 |z 9781787566002 |w (OCoLC)1023605369 |
| 830 | 0 | |a Research in law and economics (Emerald Publishing (Firm)) ; |v v. 28. | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBU |q FWS_PDA_EBU |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1708662 |3 Volltext |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH33899879 | ||
| 938 | |a Askews and Holts Library Services |b ASKH |n AH33899877 | ||
| 938 | |a EBL - Ebook Library |b EBLB |n EBL5287270 | ||
| 938 | |a EBSCOhost |b EBSC |n 1708662 | ||
| 938 | |a YBP Library Services |b YANK |n 15660743 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBU | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBU-on1049149977 |
|---|---|
| _version_ | 1804748469096677377 |
| adam_text | |
| any_adam_object | |
| author2 | Langenfeld, James Galeano, Edwin |
| author2_role | edt edt |
| author2_variant | j l jl e g eg |
| author_facet | Langenfeld, James Galeano, Edwin |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | K - Law |
| callnumber-label | KF3827 |
| callnumber-raw | KF3827.A58 |
| callnumber-search | KF3827.A58 |
| callnumber-sort | KF 43827 A58 |
| callnumber-subject | KF - United States |
| collection | ZDB-4-EBU |
| contents | Front Cover; Healthcare Antitrust, Settlements, and the Federal Trade Commission; Copyright Page; Contents; About the Editors; List of Contributors; Acknowledgments; Introduction; "To Know Where You're Going, Look at Where You've Been"; Introduction; Pharmaceuticals: A Case of FTC Investment and Consumption; Provider Mergers: Clear Guidance from Litigated Cases; No Need for Special Rules for Healthcare Markets; ACKNOWLEDGMENT; Notes; References; Actavis, Authorized Generics, and the Future of Antitrust Law; Introduction; Background; Merits Analysis; Hatch-Waxman Background. Applying Merits Analysis to Hatch-WaxmanPre-Actavis Analysis of Hatch-Waxman Settlements; Federal Trade Commission v. Actavis; Understanding Actavis; Bribing Generics to Stay Out of the Market; Hypotheticals; H1. The Litigants' Expectations about Litigation are Correct; H2. The Parties Both Believe that the Brand Holds a "Strong" Patent; H3. No Alignment in Expectations; H4. Pessimistic Litigants Split the Patent Life with No Net Reverse Payment; H5a. The Brand Prevailed in a Litigation Challenging Patent Validity but Settles a Second Challenge. H5b. The Settlement Fails and the Parties Continue to LitigateH6. No Alignment in Expectations but Risk Aversion Leads to Settlements; H7a. Efficiencies; H7b. Efficiencies; Some Conclusions Derived from the Hypotheticals; Without Legal Limitations, There Will Be Anticompetitive Hatch-Waxman Settlements; Actavis Abandons the Preponderance-of-the-Evidence Standard for Determining Anticompetitive Effects; If the Parties' Expectations Are Correct, Absent Risk Aversion, on Average, Consumers Are Often No Better Off with the Acta ... ; Not Accounting for Risk Profiles May Harm Consumers. Actavis Relies on Intent EvidenceActavis Relies on the Intent of the Brand, Not Necessarily the Generic; If the Parties' Expectations Are Not Correct, the Actavis Solution May Make Consumers Worse Off than Merits Analysis; Even in a Settlement without a Net Reverse Payment, One of the Parties May Intend to Achieve an Anticompetitive Effect; Actavis Circumvents Other Elements of Conventional Antitrust Analysis; A Red Flag Is Central to the Actavis Methodology; There Is No Easy Means of Balancing Efficiencies against Anticompetitive Effects Using the Actavis Methodology. Additional Unresolved Actavis IssuesAntitrust Injury; Damages; The Slippery Slope of Mt. Actavis; The No-AG Agreement; Applying Actavis to Difficult IP/Antitrust Cases; Antitrust Guidelines for the Licensing of Intellectual Property; Actavis beyond the IP/Antitrust Interface; Where Are We Going?; Notes; Acknowledgment; References; Solving the Product-Hopping Conundrum through Safe Harbors and a No-Economic-Sense Test; Introduction; Product Hopping; Forms of Product Hopping; Hatch-Waxman Act; State Drug Product Selection Laws; Timing of Generic Entry; A New Product-Hopping Framework. |
| ctrlnum | (OCoLC)1049149977 |
| dewey-full | 344.730321 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 344 - Labor, social, education & cultural law |
| dewey-raw | 344.730321 |
| dewey-search | 344.730321 |
| dewey-sort | 3344.730321 |
| dewey-tens | 340 - Law |
| discipline | Rechtswissenschaft |
| edition | First edition. |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06306cam a2200733 i 4500</leader><controlfield tag="001">ZDB-4-EBU-on1049149977</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20240405112445.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu|||unuuu</controlfield><controlfield tag="008">180821s2018 enk ob 001 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">N$T</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">N$T</subfield><subfield code="d">N$T</subfield><subfield code="d">EBLCP</subfield><subfield code="d">YDX</subfield><subfield code="d">OCLCF</subfield><subfield code="d">NLE</subfield><subfield code="d">MERUC</subfield><subfield code="d">COO</subfield><subfield code="d">UKMGB</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OTZ</subfield><subfield code="d">CAUOI</subfield><subfield code="d">UKAHL</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">VT2</subfield><subfield code="d">K6U</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">018893821</subfield><subfield code="2">Uk</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">1049603806</subfield><subfield code="a">1049935205</subfield><subfield code="a">1170519398</subfield><subfield code="a">1171039283</subfield><subfield code="a">1262687076</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781787565999</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1787565998</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781787566019</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1787566013</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781787566002</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">1787566005</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1049149977</subfield><subfield code="z">(OCoLC)1049603806</subfield><subfield code="z">(OCoLC)1049935205</subfield><subfield code="z">(OCoLC)1170519398</subfield><subfield code="z">(OCoLC)1171039283</subfield><subfield code="z">(OCoLC)1262687076</subfield></datafield><datafield tag="037" ind1=" " ind2=" "><subfield code="a">9781787566019</subfield><subfield code="b">Emerald Publishing</subfield></datafield><datafield tag="043" ind1=" " ind2=" "><subfield code="a">n-us---</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">KF3827.A58</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">LAW</subfield><subfield code="x">001000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">KC</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="080" ind1=" " ind2=" "><subfield code="a">343</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">344.730321</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Healthcare antitrust, settlements, and the Federal Trade Commission /</subfield><subfield code="c">edited by James Langenfeld, Edwin Galeano.</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">First edition.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bingley, UK :</subfield><subfield code="b">Emerald Publishing,</subfield><subfield code="c">2018.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Research in law and economics ;</subfield><subfield code="v">volume 28</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Online resource; title from PDF title page (EBSCO, viewed August 23, 2018).</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Front Cover; Healthcare Antitrust, Settlements, and the Federal Trade Commission; Copyright Page; Contents; About the Editors; List of Contributors; Acknowledgments; Introduction; "To Know Where You're Going, Look at Where You've Been"; Introduction; Pharmaceuticals: A Case of FTC Investment and Consumption; Provider Mergers: Clear Guidance from Litigated Cases; No Need for Special Rules for Healthcare Markets; ACKNOWLEDGMENT; Notes; References; Actavis, Authorized Generics, and the Future of Antitrust Law; Introduction; Background; Merits Analysis; Hatch-Waxman Background.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Applying Merits Analysis to Hatch-WaxmanPre-Actavis Analysis of Hatch-Waxman Settlements; Federal Trade Commission v. Actavis; Understanding Actavis; Bribing Generics to Stay Out of the Market; Hypotheticals; H1. The Litigants' Expectations about Litigation are Correct; H2. The Parties Both Believe that the Brand Holds a "Strong" Patent; H3. No Alignment in Expectations; H4. Pessimistic Litigants Split the Patent Life with No Net Reverse Payment; H5a. The Brand Prevailed in a Litigation Challenging Patent Validity but Settles a Second Challenge.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">H5b. The Settlement Fails and the Parties Continue to LitigateH6. No Alignment in Expectations but Risk Aversion Leads to Settlements; H7a. Efficiencies; H7b. Efficiencies; Some Conclusions Derived from the Hypotheticals; Without Legal Limitations, There Will Be Anticompetitive Hatch-Waxman Settlements; Actavis Abandons the Preponderance-of-the-Evidence Standard for Determining Anticompetitive Effects; If the Parties' Expectations Are Correct, Absent Risk Aversion, on Average, Consumers Are Often No Better Off with the Acta ... ; Not Accounting for Risk Profiles May Harm Consumers.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Actavis Relies on Intent EvidenceActavis Relies on the Intent of the Brand, Not Necessarily the Generic; If the Parties' Expectations Are Not Correct, the Actavis Solution May Make Consumers Worse Off than Merits Analysis; Even in a Settlement without a Net Reverse Payment, One of the Parties May Intend to Achieve an Anticompetitive Effect; Actavis Circumvents Other Elements of Conventional Antitrust Analysis; A Red Flag Is Central to the Actavis Methodology; There Is No Easy Means of Balancing Efficiencies against Anticompetitive Effects Using the Actavis Methodology.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Additional Unresolved Actavis IssuesAntitrust Injury; Damages; The Slippery Slope of Mt. Actavis; The No-AG Agreement; Applying Actavis to Difficult IP/Antitrust Cases; Antitrust Guidelines for the Licensing of Intellectual Property; Actavis beyond the IP/Antitrust Interface; Where Are We Going?; Notes; Acknowledgment; References; Solving the Product-Hopping Conundrum through Safe Harbors and a No-Economic-Sense Test; Introduction; Product Hopping; Forms of Product Hopping; Hatch-Waxman Act; State Drug Product Selection Laws; Timing of Generic Entry; A New Product-Hopping Framework.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This volume of Research in Law and Economics contains articles that address important legal and economic developments in the areas of healthcare, intellectual property and labor settlements, competitive effects, cartel overcharges, and the U.S. Federal Trade Commission (""FTC"").</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Antitrust law</subfield><subfield code="z">United States.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Medical care</subfield><subfield code="x">Law and legislation</subfield><subfield code="z">United States.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Economics.</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LAW</subfield><subfield code="x">Administrative Law & Regulatory Practice.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antitrust law</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medical care</subfield><subfield code="x">Law and legislation</subfield><subfield code="2">fast</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">United States</subfield><subfield code="2">fast</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Langenfeld, James,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Galeano, Edwin,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">Healthcare antitrust, settlements, and the Federal Trade Commission (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCGGjbHQqHHDhBTwQ684MKd</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="t">Healthcare antitrust, settlements, and the Federal Trade Commission.</subfield><subfield code="b">First edition.</subfield><subfield code="d">Bingley, UK : Emerald Publishing, 2018</subfield><subfield code="z">1787566005</subfield><subfield code="z">9781787566002</subfield><subfield code="w">(OCoLC)1023605369</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Research in law and economics (Emerald Publishing (Firm)) ;</subfield><subfield code="v">v. 28.</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBU</subfield><subfield code="q">FWS_PDA_EBU</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1708662</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH33899879</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH33899877</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBL - Ebook Library</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL5287270</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">1708662</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">15660743</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBU</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| geographic | United States fast https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq |
| geographic_facet | United States |
| id | ZDB-4-EBU-on1049149977 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-16T15:04:22Z |
| institution | BVB |
| isbn | 9781787565999 1787565998 9781787566019 1787566013 |
| language | English |
| oclc_num | 1049149977 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource |
| psigel | ZDB-4-EBU |
| publishDate | 2018 |
| publishDateSearch | 2018 |
| publishDateSort | 2018 |
| publisher | Emerald Publishing, |
| record_format | marc |
| series | Research in law and economics (Emerald Publishing (Firm)) ; |
| series2 | Research in law and economics ; |
| spelling | Healthcare antitrust, settlements, and the Federal Trade Commission / edited by James Langenfeld, Edwin Galeano. First edition. Bingley, UK : Emerald Publishing, 2018. 1 online resource text txt rdacontent computer c rdamedia online resource cr rdacarrier Research in law and economics ; volume 28 Includes bibliographical references and index. Online resource; title from PDF title page (EBSCO, viewed August 23, 2018). Front Cover; Healthcare Antitrust, Settlements, and the Federal Trade Commission; Copyright Page; Contents; About the Editors; List of Contributors; Acknowledgments; Introduction; "To Know Where You're Going, Look at Where You've Been"; Introduction; Pharmaceuticals: A Case of FTC Investment and Consumption; Provider Mergers: Clear Guidance from Litigated Cases; No Need for Special Rules for Healthcare Markets; ACKNOWLEDGMENT; Notes; References; Actavis, Authorized Generics, and the Future of Antitrust Law; Introduction; Background; Merits Analysis; Hatch-Waxman Background. Applying Merits Analysis to Hatch-WaxmanPre-Actavis Analysis of Hatch-Waxman Settlements; Federal Trade Commission v. Actavis; Understanding Actavis; Bribing Generics to Stay Out of the Market; Hypotheticals; H1. The Litigants' Expectations about Litigation are Correct; H2. The Parties Both Believe that the Brand Holds a "Strong" Patent; H3. No Alignment in Expectations; H4. Pessimistic Litigants Split the Patent Life with No Net Reverse Payment; H5a. The Brand Prevailed in a Litigation Challenging Patent Validity but Settles a Second Challenge. H5b. The Settlement Fails and the Parties Continue to LitigateH6. No Alignment in Expectations but Risk Aversion Leads to Settlements; H7a. Efficiencies; H7b. Efficiencies; Some Conclusions Derived from the Hypotheticals; Without Legal Limitations, There Will Be Anticompetitive Hatch-Waxman Settlements; Actavis Abandons the Preponderance-of-the-Evidence Standard for Determining Anticompetitive Effects; If the Parties' Expectations Are Correct, Absent Risk Aversion, on Average, Consumers Are Often No Better Off with the Acta ... ; Not Accounting for Risk Profiles May Harm Consumers. Actavis Relies on Intent EvidenceActavis Relies on the Intent of the Brand, Not Necessarily the Generic; If the Parties' Expectations Are Not Correct, the Actavis Solution May Make Consumers Worse Off than Merits Analysis; Even in a Settlement without a Net Reverse Payment, One of the Parties May Intend to Achieve an Anticompetitive Effect; Actavis Circumvents Other Elements of Conventional Antitrust Analysis; A Red Flag Is Central to the Actavis Methodology; There Is No Easy Means of Balancing Efficiencies against Anticompetitive Effects Using the Actavis Methodology. Additional Unresolved Actavis IssuesAntitrust Injury; Damages; The Slippery Slope of Mt. Actavis; The No-AG Agreement; Applying Actavis to Difficult IP/Antitrust Cases; Antitrust Guidelines for the Licensing of Intellectual Property; Actavis beyond the IP/Antitrust Interface; Where Are We Going?; Notes; Acknowledgment; References; Solving the Product-Hopping Conundrum through Safe Harbors and a No-Economic-Sense Test; Introduction; Product Hopping; Forms of Product Hopping; Hatch-Waxman Act; State Drug Product Selection Laws; Timing of Generic Entry; A New Product-Hopping Framework. This volume of Research in Law and Economics contains articles that address important legal and economic developments in the areas of healthcare, intellectual property and labor settlements, competitive effects, cartel overcharges, and the U.S. Federal Trade Commission (""FTC""). Antitrust law United States. Medical care Law and legislation United States. Economics. bicssc LAW Administrative Law & Regulatory Practice. bisacsh Antitrust law fast Medical care Law and legislation fast United States fast https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq Langenfeld, James, editor. Galeano, Edwin, editor. has work: Healthcare antitrust, settlements, and the Federal Trade Commission (Text) https://id.oclc.org/worldcat/entity/E39PCGGjbHQqHHDhBTwQ684MKd https://id.oclc.org/worldcat/ontology/hasWork Print version: Healthcare antitrust, settlements, and the Federal Trade Commission. First edition. Bingley, UK : Emerald Publishing, 2018 1787566005 9781787566002 (OCoLC)1023605369 Research in law and economics (Emerald Publishing (Firm)) ; v. 28. FWS01 ZDB-4-EBU FWS_PDA_EBU https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1708662 Volltext |
| spellingShingle | Healthcare antitrust, settlements, and the Federal Trade Commission / Research in law and economics (Emerald Publishing (Firm)) ; Front Cover; Healthcare Antitrust, Settlements, and the Federal Trade Commission; Copyright Page; Contents; About the Editors; List of Contributors; Acknowledgments; Introduction; "To Know Where You're Going, Look at Where You've Been"; Introduction; Pharmaceuticals: A Case of FTC Investment and Consumption; Provider Mergers: Clear Guidance from Litigated Cases; No Need for Special Rules for Healthcare Markets; ACKNOWLEDGMENT; Notes; References; Actavis, Authorized Generics, and the Future of Antitrust Law; Introduction; Background; Merits Analysis; Hatch-Waxman Background. Applying Merits Analysis to Hatch-WaxmanPre-Actavis Analysis of Hatch-Waxman Settlements; Federal Trade Commission v. Actavis; Understanding Actavis; Bribing Generics to Stay Out of the Market; Hypotheticals; H1. The Litigants' Expectations about Litigation are Correct; H2. The Parties Both Believe that the Brand Holds a "Strong" Patent; H3. No Alignment in Expectations; H4. Pessimistic Litigants Split the Patent Life with No Net Reverse Payment; H5a. The Brand Prevailed in a Litigation Challenging Patent Validity but Settles a Second Challenge. H5b. The Settlement Fails and the Parties Continue to LitigateH6. No Alignment in Expectations but Risk Aversion Leads to Settlements; H7a. Efficiencies; H7b. Efficiencies; Some Conclusions Derived from the Hypotheticals; Without Legal Limitations, There Will Be Anticompetitive Hatch-Waxman Settlements; Actavis Abandons the Preponderance-of-the-Evidence Standard for Determining Anticompetitive Effects; If the Parties' Expectations Are Correct, Absent Risk Aversion, on Average, Consumers Are Often No Better Off with the Acta ... ; Not Accounting for Risk Profiles May Harm Consumers. Actavis Relies on Intent EvidenceActavis Relies on the Intent of the Brand, Not Necessarily the Generic; If the Parties' Expectations Are Not Correct, the Actavis Solution May Make Consumers Worse Off than Merits Analysis; Even in a Settlement without a Net Reverse Payment, One of the Parties May Intend to Achieve an Anticompetitive Effect; Actavis Circumvents Other Elements of Conventional Antitrust Analysis; A Red Flag Is Central to the Actavis Methodology; There Is No Easy Means of Balancing Efficiencies against Anticompetitive Effects Using the Actavis Methodology. Additional Unresolved Actavis IssuesAntitrust Injury; Damages; The Slippery Slope of Mt. Actavis; The No-AG Agreement; Applying Actavis to Difficult IP/Antitrust Cases; Antitrust Guidelines for the Licensing of Intellectual Property; Actavis beyond the IP/Antitrust Interface; Where Are We Going?; Notes; Acknowledgment; References; Solving the Product-Hopping Conundrum through Safe Harbors and a No-Economic-Sense Test; Introduction; Product Hopping; Forms of Product Hopping; Hatch-Waxman Act; State Drug Product Selection Laws; Timing of Generic Entry; A New Product-Hopping Framework. Antitrust law United States. Medical care Law and legislation United States. Economics. bicssc LAW Administrative Law & Regulatory Practice. bisacsh Antitrust law fast Medical care Law and legislation fast |
| title | Healthcare antitrust, settlements, and the Federal Trade Commission / |
| title_auth | Healthcare antitrust, settlements, and the Federal Trade Commission / |
| title_exact_search | Healthcare antitrust, settlements, and the Federal Trade Commission / |
| title_full | Healthcare antitrust, settlements, and the Federal Trade Commission / edited by James Langenfeld, Edwin Galeano. |
| title_fullStr | Healthcare antitrust, settlements, and the Federal Trade Commission / edited by James Langenfeld, Edwin Galeano. |
| title_full_unstemmed | Healthcare antitrust, settlements, and the Federal Trade Commission / edited by James Langenfeld, Edwin Galeano. |
| title_short | Healthcare antitrust, settlements, and the Federal Trade Commission / |
| title_sort | healthcare antitrust settlements and the federal trade commission |
| topic | Antitrust law United States. Medical care Law and legislation United States. Economics. bicssc LAW Administrative Law & Regulatory Practice. bisacsh Antitrust law fast Medical care Law and legislation fast |
| topic_facet | Antitrust law United States. Medical care Law and legislation United States. Economics. LAW Administrative Law & Regulatory Practice. Antitrust law Medical care Law and legislation United States |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1708662 |
| work_keys_str_mv | AT langenfeldjames healthcareantitrustsettlementsandthefederaltradecommission AT galeanoedwin healthcareantitrustsettlementsandthefederaltradecommission |